

**Severe Asthma Update: Clinical Management and Key Considerations to Target Optimal Patient Care**  
**Tweetorial #3 Reference List**

**Tweet #3:**

Agache I, Akdis C, Akdis M, et al. EAACI biologicals guidelines—recommendations for severe asthma. *Allergy*. 2020. doi:10.1111/all.14425

**Tweet #4:**

Global Initiative for Asthma. *Difficult-To-Treat & Severe Asthma In Adolescents And Adult Patients Diagnosis And Management*. Global Initiative for Asthma; 2020. Accessed October 7, 2020.  
<https://ginasthma.org/wp-content/uploads/2019/04/GINA-Severe-asthma-Pocket-Guide-v2.0-wms-1.pdf>

**Tweet #6:**

Global Initiative for Asthma. *Difficult-To-Treat & Severe Asthma In Adolescents And Adult Patients Diagnosis And Management*. Global Initiative for Asthma; 2020. Accessed October 7, 2020.  
<https://ginasthma.org/wp-content/uploads/2019/04/GINA-Severe-asthma-Pocket-Guide-v2.0-wms-1.pdf>

**Tweet #8:**

Global Initiative for Asthma. *Difficult-To-Treat & Severe Asthma In Adolescents And Adult Patients Diagnosis And Management*. Global Initiative for Asthma; 2020. Accessed October 7, 2020.  
<https://ginasthma.org/wp-content/uploads/2019/04/GINA-Severe-asthma-Pocket-Guide-v2.0-wms-1.pdf>

**Tweet #9:**

Bel E, Wenzel S, Thompson P, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. *N Engl J Med*. 2014;371(13):1189-1197. doi:10.1056/nejmoa1403291

Nair P, Wenzel S, Rabe K, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. *N Engl J Med*. 2017;376(25):2448-2458. doi:10.1056/nejmoa1703501

Rabe K, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. *N Engl J Med*. 2018;378(26):2475-2485. doi:10.1056/nejmoa1804093